Cohance Lifesciences Limited — Others, 07-04-2025: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Suven Pharmaceuticals Limited has announced a board meeting to discuss its financial results for the quarter and half-year ended March 31, 2025. The company provided confirmation certificates regarding the dematerialization and rematerialization of securities during this period, as verified by KFin Technologies Limited. This ensures transparency and compliance with SEBI regulations, reinforcing shareholder confidence. Investors may view this as a positive outlook, reflecting the company’s commitment to maintaining proper governance and operational integrity, potentially influencing market sentiment favorably.